Skip to main content
Clinical Trials/DRKS00025056
DRKS00025056
Completed
Phase 4

Treatment of wound healing disorders in patients with diabetic foot syndrome caused by diabetic neuropathy (neuropathic foot), or diabetic angiopathy (gangrene) with the medical device TOXAPREVENT SKIN® skin powder and early detection of a possible wound infection by MEANS of VOC analysis by MCC-IMS - MANC-MCC-IMS-202005

FROXIMUN AG0 sites50 target enrollmentApril 14, 2021

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
E14.7
Sponsor
FROXIMUN AG
Enrollment
50
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 14, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Indication according to the target
  • Healthy skin areas present as a control area
  • Patients with diabetic neuropathy (neuropathic foot), or diabetic angiopathy (gangrene)

Exclusion Criteria

  • Severe HKE (cardiovascular disease)
  • other primarily chronic skin diseases
  • Higher degree of liver and/or renal failure
  • higher\-grade dementia/ Delir
  • Septic disease
  • Lack of compliance
  • Lack of consent

Outcomes

Primary Outcomes

Not specified

Similar Trials